Combining ICB with RT, ATR, DNA-PKcs, and PARP inhibitors has been shown to improve outcomes in some cancer types, in large part due the activation of innate immune responses driven by the cGAS-STING pathway [209,210,211,212,213,214,215,216,217,218]. This evidence concerns the gene PARP1 and cancer.